HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology
HCG clinicians contributing to one of the largest bodies of oncology research from India
HCG clinicians contributing to one of the largest bodies of oncology research from India
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
Glucon-D maintained its leadership position with a 59% MAT market share
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Subscribe To Our Newsletter & Stay Updated